<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433016</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-BID-0411</org_study_id>
    <nct_id>NCT01433016</nct_id>
  </id_info>
  <brief_title>Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI</brief_title>
  <acronym>OBT for HCC</acronym>
  <official_title>Evaluation of the Capability of the ¹³C-Octanoate Breath Test (OBT) Measurement in Patients With Chronic Liver Disease to Differentiate Between Presence and Absence of HCC Determined by MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toronto General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Exalenz clinical investigation is a multicenter, non-randomized, study of the
      ¹³C-Octanoate Breath Test (OBT). The present study is a feasibility trial, which aims to
      evaluate the capability of the OBT measurement to differentiate between presence and absence
      of HCC determined by Magnetic Resonance Imaging (MRI) in patients with chronic liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Octanoate Breath Test (OBT) developed by Exalenz is performed by the BreathID System
      consists of the BreathID device and a test kit containing a nasal cannula, a calibration gas
      container and a non-radioactive isotope ¹³C- Octanoate solution, and measures and computes
      the ratio between ¹³CO2 and 12CO2 in the patient's exhaled breath.

      This study's aim is to provide data on this novel system to dynamically and accurately assess
      liver function at the bed side. It is hoped that the system will provide prognostic
      information faster than is achieved at present with traditional methods. It is hypothesized
      that in the future the OBT may have an impact on decision making and clinical practice in
      this group of HCC patients, allowing a greater chance for proper management and hence
      survival.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to budgetary issues, the company has decided to focus on other applications at this stage.
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PDR Peak</measure>
    <time_frame>At study day one after one hour</time_frame>
    <description>PDR peak - the rate at which the 13C labeled substrate is metabolized, percentage dose recovery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Liver Disease</condition>
  <condition>Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Octanaote Breath Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Octanoate breath test will be performed on this single arm population</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13C Sodium Octanoate</intervention_name>
    <description>13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.</description>
    <arm_group_label>Octanaote Breath Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patients with chronic liver disease at risk for HCC.

          -  Age &gt; 18 years.

          -  Patient has an MRI result (positive or negative for HCC) up to 3 months prior to
             recruitment or will be scheduled for an MRI during the trial period.

          -  Patient is naïve to any HCC treatment.

        Exclusion Criteria:

          -  Underwent any RFA or TACE or Oral HCC treatments.

          -  Portal vein thrombosis.

          -  Prior TIPS placement.

          -  Severe congestive heart failure (LVEF on echocardiogram &lt; 20%).

          -  Severe pulmonary hypertension (By echocardiogram, PAS &gt;45 mmHg).

          -  Uncontrolled diabetes mellitus (HBA1C &gt;9.5%).

          -  Any autoimmune disorder, which is currently being treated with prednisone or any other
             immune suppressive medication.

          -  Previous surgical bypass surgery for morbid obesity (BMI &gt;45).

          -  Extensive small bowel resection.

          -  Patients currently receiving total parenteral nutrition if they have contraindications
             to oral drugs.

          -  Women who are pregnant or breast feeding.

          -  Patients with an acute current exacerbation of chronic obstructive pulmonary disease
             or bronchial asthma.

          -  Patient has taken drugs that can interfere with octanoate metabolism or can also cause
             NAFLD independent of the metabolic syndrome, including: corticosteroids, amiodarone,
             tetracycline, valproic acid, methotrexate, stavudine, zidovudine.

          -  Patient, based on the opinion of the investigator, should not be enrolled into this
             study.

          -  Patient is unable or unwilling to sign informed consent.

          -  Patients that are participating in other clinical trials evaluating experimental
             treatments or procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morris Sherman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <results_first_submitted>February 11, 2014</results_first_submitted>
  <results_first_submitted_qc>February 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2014</results_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC Hepatocellular carcinoma</keyword>
  <keyword>OBT Octanoate Breath Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Suspected HCC</title>
          <description>Subjects at high risk for hepatocellular carcinoma (HCC), such as cirrhotics and patients with advanced liver disease will be asked to perform a single Octanoate Breath test, where their breath will be analyzed before and after ingestion of 100 milligrams of Octanoate dissolved in a cup of tap water. The actual breath test procedure lasts approximately one hour.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Cirrhotic patients with suspected HCC</population>
      <group_list>
        <group group_id="B1">
          <title>Suspected HCC</title>
          <description>Subjects at high risk for hepatocellular carcinoma (HCC), such as cirrhotics and patients with advanced liver disease will be asked to perform a single Octanoate Breath test, where their breath will be analyzed before and after ingestion of 100 milligrams of Octanoate dissolved in a cup of tap water. The actual breath test procedure lasts approximately one hour.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PDR Peak</title>
        <description>PDR peak - the rate at which the 13C labeled substrate is metabolized, percentage dose recovery.</description>
        <time_frame>At study day one after one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suspected HCC</title>
            <description>Subjects at high risk for Hepatocellular carcinoma (HCC), such as cirrhotics and patients with advanced liver disease</description>
          </group>
        </group_list>
        <measure>
          <title>PDR Peak</title>
          <description>PDR peak - the rate at which the 13C labeled substrate is metabolized, percentage dose recovery.</description>
          <units>percentage of dose recovery</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.78" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the one-time Octanoate Breath Test, up to two hours.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Suspected HCC</title>
          <description>Subjects at high risk for Hepatocellular carcinoma (HCC), such as cirrhotics and patients with advanced liver disease</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trials Manager</name_or_title>
      <organization>Exalenz Bioscience</organization>
      <phone>+972-8-9737513</phone>
      <email>avrahamh@exalenz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

